BioCryst Pharmaceuticals, Inc.
BCRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.5B
$9.96
▼ -1.29%
P/E
-6.68
Mkt Cap
$2.5B
52-Wk Range
$6.00–$11.22
52-Week Range
$6.00 - $11.22
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 21.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary oral small-molecule drug discovery platform with focus on protease and complement inhibitors
- Established commercial infrastructure with FDA-approved marketed products generating recurring revenue
- Strategic partnerships with major pharmaceutical companies (Seqirus, Shionogi, Mundipharma) and government agencies (NIAID, BARDA) providing validation and development support
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Revenue decline expected
Expansion of ORLADEYO market penetration in hereditary angioedema patient population
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+18.1% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BCRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 5, 2026
Reported EPS of $0.30 vs $0.15 consensus (+94.5% surprise). Revenue of $218.3M vs $183.3M expected (+19.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+94.5%
Revenue trend · last 8Q
—
+41%
+57%
+49%
+36%
+209%
+7%
+34%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$117.1M
$131.5M
$145.5M
$163.4M
$159.4M
$406.6M
$156.4M
$218.3M
Margins · last 8Q
Gross
98.2%
Operating
45.1%
Profit
35.9%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Jul 7, 2026
vs Industry
How BCRX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related